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Abstract TRAIL-R3 is a decoy receptor for TRAIL (tumor
necrosis factor-related apoptosis-inducing ligand), a member of
the tumor necrosis factor ligand family. In several cell types
decoy receptors inhibit TRAIL-induced apoptosis by binding
TRAIL and preventing its binding to TRAIL pro-apoptotic re-
ceptors. Here we report the cloning of the promoter region of
human TRAIL-R3 and the mapping of the transcriptional start
sites. This gene contains a consensus TATA box and the min-
imal promoter lies within the ¢rst 33 nucleotides upstream of the
transcription start site. Transient transfection assays of lucifer-
ase reporter plasmids demonstrate that human TRAIL-R3 pro-
moter can be induced in doxorubicin-treated MCF-7 cells in a
p53-independent manner.
) 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
Key words: TRAIL-R3; Decoy receptor; Promoter structure;
Transcription; Apoptosis ; Doxorubicin
1. Introduction
TRAIL (tumor necrosis factor (TNF)-related apoptosis-in-
ducing Ligand) is a member of the TNF ligand family [1,2].
As with other members, TRAIL is a type II transmembrane
protein which is able to induce apoptosis after binding to its
pro-apoptotic membrane receptors, TRAIL-R1 (DR4) and
TRAIL-R2 (DR5/TRICK2/KILLER) [3,4]. Unlike Fas ligand
and TNF-K, TRAIL selectively induces apoptosis in tumor
cells without being toxic in non-transformed cells [5]. This
observation raises expectations regarding the clinical use of
TRAIL as a new anti-tumor agent. Great e¡orts are being
made to elucidate TRAIL biology and the mechanisms of
TRAIL-induced apoptosis. TRAIL binds to four membrane
receptors [6]. The pro-apoptotic receptors TRAIL-R1 [7] and
TRAIL-R2 [8] contain a cytoplasmic death domain which is
involved in the apoptotic signal. In contrast, the decoy recep-
tors TRAIL-R3 (DcR1/TRID/LIT) [7,9^11] and TRAIL-R4
(DcR2/TRUNDD) [12] do not signal apoptosis since they
either lack the intracellular death domain (TRAIL-R3) or
have it truncated (TRAIL-R4). In several cell types the decoy
receptors have been reported to inhibit TRAIL-induced apo-
ptosis by competing the binding of TRAIL to the pro-apo-
ptotic receptors [13]. However, other mechanisms can also be
responsible for the inhibition of TRAIL-mediated apoptosis
as in certain cells lacking decoy receptors resistance to TRAIL
has been reported [14,15].
TRAIL-R3 is a glycosylphosphatidylinositol (GPI)-an-
chored cell surface protein that may prevent TRAIL from
binding to pro-apoptotic receptors. In this respect, cleavage
of the GPI anchor by phospholipase C treatment of TRAIL-
R3-expressing cells could result in marked sensitization to
TRAIL-induced apoptosis [16]. In addition, forced expression
of TRAIL-R3 in TRAIL-sensitive cells reduces ligand-induced
apoptosis [7,9]. Interestingly, TRAIL-R3 is highly expressed
in a majority of normal human tissues while very low levels of
mRNA were found when di¡erent cell lines representing var-
ious tumor types were analyzed [7,9,10]. These observations
have made TRAIL-R3 a possible marker for tumor resistance.
Regulation of TRAIL receptors has been commonly studied
at mRNA and protein levels, but little is known regarding the
basic structure of TRAIL receptor promoters and the tran-
scription factors that control their expression. The involve-
ment of p53 in the regulation of the TRAIL-R2 promoter
has been described [17], and hypermethylation of the human
TRAIL-R3 and TRAIL-R4 promoters has been suggested to
be important for the down-regulation of these receptors in
neuroblastoma and other tumor types [18]. It has been re-
cently reported that activator protein 1 (AP-1) regulates
TRAIL-R1 expression via the AP-1 binding site located at
3350/3344 within the gene promoter region [19]. Earlier ¢nd-
ings demonstrated that TRAIL-R3 mRNA levels are en-
hanced by genotoxic agents and ionizing radiation in a p53
wild-type cell line [20]. Later, it was shown that induction of
expression of the TRAIL-R3 gene in response to DNA dam-
age is restricted to p53 wild-type cell lines [21]. In addition,
transcription factors of the NF-UB family may also be in-
volved in the regulation of TRAIL-R3 gene expression [22].
Despite the publication of most of the human genome se-
quence [23], there are still some gaps and so far the promoter
structure and the genomic organization of human TRAIL-R3
are not available. In this paper we describe the TRAIL-R3
promoter sequence and we identify the transcription initiation
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sites, as well as minimal functional promoter elements. The
induction of promoter activity by the anti-tumor drug doxo-
rubicin is also addressed.
2. Materials and methods
2.1. Cell culture
MCF-7 human breast cancer cells were maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum, 2 mM L-gluta-
mine and 40 mg/l gentamicin at 37‡C in a humidi¢ed 5% CO2/95% air
incubator. MCF-7 cells stably expressing the human papillomavirus
type 16 E6 protein (MCF-7E6) were maintained in culture as described
[24]. Doxorubicin (Sigma) was employed at 500 ng/ml.
2.2. Cloning of the human TRAIL-R3 promoter
The genomic sequence lying upstream of the human TRAIL-R3
cDNA was isolated employing the Human Promoter Finder DNA
Walking Kit (Clontech) according to the manufacturer’s instructions.
Polymerase chain reactions (PCRs) were carried out using human
TRAIL-R3-speci¢c primers corresponding to the 5P region of the
published cDNA sequence (GenBank accession number AF012536)
and the supplied adapter primers. The sequences of the gene-speci¢c
primers were TR3#3rp (5P-CTATCAGAAATCGTTGGCTGAGTT-
CCCTAACGGTAG-3) and TR3#4rp (5P-CTGAGTTCGTGCGCG-
TGGAGAGGTTCC-3P). A single 2.7 kb PCR product from the sec-
ondary reactions was cloned directly into the pGEM-T vector
(Promega).
2.3. Plasmid constructs
TRAIL-R3 promoter constructs were created by cloning a 1683 bp
BamHI^SalI DNA fragment from the pGEM-T 2.7 kb construct de-
scribed above into the BamHI^SalI sites of the pXP2-Luc reporter
plasmid [25]. The 506 bp, 126 bp and 33 bp pXP2 reporter constructs
were made from the 1683 bp pXP2 plasmid by using unique restric-
tion sites within the TRAIL-R3-speci¢c DNA fragment. This con-
struct was digested with BamHI combined with either HindIII, StuI
or SacII enzymes, the 5P ends were re¢lled and the blunt-ended plas-
mid religated. As an internal negative control, a 2.7 kb antisense
construct was obtained by cloning the 2.7 kb SalI fragment from
the pGEMT vector into the SalI-digested pXP2 vector. The pC53-
SN3 (wt p53) plasmid was generously provided by Dr. M. Oren
(Weizmann Institute of Science, Rehovot, Israel). The pI-391LUC
reporter plasmid has been recently described [26]. All restriction en-
zymes were obtained from Roche Biochemicals. T4 DNA ligase and
T4 DNA polymerase were purchased from New England Biolabs.
2.4. S1 nuclease analysis
For nuclease S1 protection assay, an antisense oligonucleotide (5P-
TGAGTTCGTGCGCGTGGAGAGGTTCCCACAGCTGCACTGC-
CAGAATCGGAG-3P) spanning the putative initiation site (based on
the consensus TATA box detected within the promoter sequence) was
designed. This oligonucleotide was kinased using the polynucleotide
kinase enzyme (Roche Biochemicals) and [Q-32P]ATP; the labelled
oligonucleotide was puri¢ed in a G25 Spin Column (Roche Biochem-
icals).
Total RNA from MCF-7 or mouse liver cells was extracted using
Trizol Reagent (Invitrogen) according to the manufacturer’s protocol.
Fifty micrograms total RNA was precipitated and resuspended into
15 Wl of 2Uhybridization bu¡er. The RNA solution was then mixed
with 106 cpm of 32P-labelled oligonucleotide and 15 Wl of formamide,
heated at 68‡C for 10 min and incubated overnight at 37‡C. After this
incubation, samples were treated with S1 nuclease (Gibco-BRL) for 30
min at 37‡C according to the manufacturer’s instructions. The S1-
digested products were analyzed on a denaturing 8% polyacrylamide
gel. Four microliters of the non-digested and diluted (1/800) labelled
oligonucleotide (i.e. probe) was run at the same time. For a detailed
protocol visit our website: http://www2.cbm.uam.es/bc-015.
2.5. Primer extension assays
Primer extension assays were performed employing the M-MLV
reverse transcriptase (Gibco-BRL). The antisense oligonucleotides
TR3#1rp (5P-CGCTCTGTCCCCAGAGTTCCCTAACGGTAG-3P)
and PE#2 (5P-GCTCCTTCACCCCTTGCATCTCTGG-3P) were
end-labelled with [Q-32P]ATP to a speci¢c activity of 4^6U1010 cpm/
Wg. 1.5U106 cpm of labelled oligonucleotide was mixed with 20 Wg of
total RNA from either control or 24 h doxorubicin-treated MCF-7
(20 Wg of tRNA was employed as a negative control), dNTPs at a
¢nal concentration of 2 mM, dithiothreitol (¢nal concentration
0.01 M) and First Strand Bu¡er. The samples were heated at 68‡C
for 5 min and then allowed to cool down to 42‡C. The annealed
primers were extended with M-MLV reverse transcriptase for 1 h at
42‡C; the extended products were analyzed on denaturing 8% poly-
acrylamide gels. Sequencing reactions performed on a promoter-con-
taining plasmid with the same oligonucleotides (Sequenase Quick-De-
nature plasmid sequencing kit, USB) were run at the same time for
accurate determination of the 5P-end termini.
2.6. Transient transfection and reporter activity assay
Transient transfection experiments were performed in MCF-7 cells
by using a modi¢ed version of the calcium phosphate precipitation
procedure [27]. Approximately 90% con£uent cell cultures were split
1/12 onto 35 mm diameter tissue culture dishes. The following day the
medium was replaced with 1.4 ml of fresh supplemented Dulbecco’s
modi¢ed Eagle’s medium; 4 h later DNA precipitates were added
dropwise to cells. The cells were left in contact with the precipitates
for 12 h, and then the medium was replaced. Precipitates were gen-
erated by mixing 0.5 ml of 1UHEPES-bu¡ered saline (0.5% HEPES,
0.8% NaCl, 0.1% dextrose, 0.01% anhydrous Na2HPO4, 0.37% KCl,
pH adjusted to 7.05) with 5.0 Wg of plasmid DNA (typically, 0.5 Wg
luciferase reporter plasmid, 0.25 ng of L-galactosidase (L-gal) plasmid
plus carrier DNA (pGL3Basic) up to 5.0 Wg) followed by the addition
of 5 Wl of 2.5 M CaCl2. Precipitates were allowed to form at room
temperature for 20 min before addition to the cells. For doxorubicin
treatment, cells were allowed to grow for 10 h after transfection and
then overnight treated with 500 ng/ml doxorubicin For a detailed
protocol visit our website: http://www2.cbm.uam.es/bc-015.
Luciferase activity was measured according to the instructions of
the Luciferase system kit (Promega) in a luminometer Monolight 2010
(Analytical Luminescence Laboratory, San Diego, CA, USA). Trans-
fection e⁄ciency was normalized by cotransfection with 0.25 ng of the
pCMV-L-gal (Promega). Transfection experiments were performed in
triplicate.
2.7. Reverse transcriptase (RT) and PCR assays
Total RNA from MCF-7 cells was isolated with the Trizol RNA
isolation system (Invitrogen) and the M-MLV reverse transcriptase
(Gibco-BRL) was used for the RT reaction, following the manufac-
turer’s recommendations. An aliquot of the RT reaction was analyzed
by PCR for both TRAIL-R3 and L-actin expression using Taq poly-
merase (Promega) and the following pairs of primers: TRAIL-R3
forward: 5P-GAAGAATTTGGTGCCAATGCCACTG-3P ; TRAIL-
R3 reverse: 5P-CTCTTGGACTTGGCTGGGAGATGTG-3P ; L-actin
forward: 5P-TGACGGGGTCACCCACACTGTGCCCATCTA-3P ;
L-actin reverse: 5P-CTAGAAGCATTTGCGGTGGACGATGGA-
GGG-3P. PCR cycle conditions were 30 s at 95‡C, 45 s at 60‡C and
1 min at 72‡C. After running PCR samples for 27 cycles, the products
were resolved on a 1% agarose gel and visualized with ethidium bro-
mide.
2.8. Computer analysis
Search for regulatory elements was performed using the
TFSEARCH ver.1.3, Threshold: 76.0 (http://www.cbrc.jp/research/
db/TFSEARCH.html).
3. Results
3.1. Cloning the 5P upstream region of the human TRAIL-R3
gene
The upstream regulatory region of the human TRAIL-R3
gene was ampli¢ed by nested PCR using two gene-speci¢c
primers, TR3#3rp and TR3#4rp, spanning regions near the
translation start site, and two adapter primers, AP-1 and
AP-2, from the adapter-ligated human genomic DNA libra-
ries. A 2.7 kb PCR product was ampli¢ed, directly cloned into
pGEMT vector and sequenced (GenBank accession number
AF524869). The 3P end of the sequence matched the gene-
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speci¢c primer and the upstream sequence of TRAIL-R3
cDNA [11].
The TRAIL-R3 upstream sequence was analyzed for regu-
latory regions using the TFSEARCH ver.1.3 program. The
presence of a consensus TATA box sequence as well as po-
tential binding sites for known transcription factors strongly
suggested that this genomic region probably contained the
human TRAIL-R3 promoter.
3.2. Identi¢cation of the transcription start site of the human
TRAIL-R3 gene
The transcription initiation start site was mapped by S1
nuclease protection and primer extension assays (Fig. 1). Be-
cause TRAIL-R3 is expressed in MCF-7 cells [28,29], total
RNA from this cell line was employed. As negative controls,
tRNA and total RNA from mouse liver cells were used. We
initially carried out S1 protection assays to test whether the
transcriptional start site mapped close to the consensus TATA
box identi¢ed within the cloned sequence (Fig. 1). As shown
in Fig. 1A, a fragment of the S1 oligonucleotide was speci¢-
cally protected when the labelled oligonucleotide was hybrid-
ized to MCF-7 RNA sample. The band indicated with an
asterisk in Fig. 1A represents a non-speci¢c signal as it is
present not only in the human and mouse lanes but also in
the lane corresponding to tRNA. To precisely locate the ini-
tiation start site, primer extension assays were performed. As
human TRAIL-R3 expression is up-regulated in MCF-7 cells
upon doxorubicin treatment (C. Ruiz de Almodo¤var and A.
Lo¤pez-Rivas, unpublished results), total RNA isolated from
MCF-7 cells, either treated with doxorubicin for 24 h or left
untreated, was employed. The extended products were specif-
ically detected only when RNA from MCF-7 cells was used
(Fig. 1B). Two major bands were selectively induced in sam-
ples from doxorubicin-treated cells. The upper site mapped
within the S1 oligonucleotide sequence whereas the second
site was located 45 nucleotides downstream. These start sites
were also mapped when a second oligonucleotide (PE#2) was
employed (data not shown). These results con¢rmed that the
upper transcriptional start site lies within the region identi¢ed
by the S1 experiment and is located 25 nucleotides down-
stream of the TATA box (Fig. 1C). This residue was given
the position +1. Recently, a TRAIL-R3-speci¢c cDNA from a
human library displaying the longest 5P end has been reported
(GenBank accession number BC017852). The fact that the
¢rst nucleotide of this sequence ¢ts to the transcriptional start
site identi¢ed above reinforces our results.
3.3. Activity of the TRAIL-R3 gene promoter
To determine whether the 5P upstream region of the human
TRAIL-R3 gene contains the basic elements for basal pro-
moter activity, a 1683 bp BamHI^SalI fragment (31641,
+42) generated by digestion of the 2.7 kb genomic was cloned
into the pXP2 vector [25], upstream of the luciferase reporter
gene. Three additional pXP2-based constructs were obtained
spanning 506, 126 and 33 bp upstream of the initiation start
site. MCF-7 cells were transiently transfected with these re-
porter plasmids and 24 h later the relative luciferase activity
Fig. 1. Characterization of the 5P end of human TRAIL-R3 tran-
scripts. A: The S1 nuclease protection assay was performed by em-
ploying the antisense S1 oligonucleotide detailed in the ¢gure. The
samples were loaded onto an 8% denaturing polyacrylamide gel.
Open arrow indicates the speci¢cally protected DNA fragment. As-
terisk denotes a non-speci¢c signal. B: Primer extension mapping of
the 5P ends in the human TRAIL-R3 mRNA. A 30-mer oligonu-
cleotide (TR3#1rp) was hybridized to total RNA from MFC-7 cells
either untreated (3) or treated with doxorubicin (doxo, 500 ng/ml)
for 24 h (+). tRNA was employed as a negative control (c). Sam-
ples were loaded onto an 8% denaturing polyacrylamide gel together
with a sequencing reaction performed with the same oligonucleotide
employed for the primer extension assay. C: Sequence of the human
TRAIL-R3 promoter showing the mRNA transcription start sites.
Arrowheads point to non-induced transcription start sites. Doxoru-
bicin-induced transcription start sites are indicated by bent arrows.
Black box denotes the TATA element. The location and name of
the oligonucleotides employed are detailed. The coding region is
shown in upper case. The major transcriptional start site is indi-
cated (+1).
Fig. 2. Deletion analysis of the human TRAIL-R3 gene promoter.
The reporter plasmids were transfected into MCF-7 cells. Restric-
tion sites employed to generate these constructs are detailed in the
schematic diagram (BHI=BamHI; HIII=HindIII; SI=StuI; SII=
SacII). Black box denotes the TATA box. One out of four indepen-
dent experiments performed is shown. Control indicates the activity
of the pXP2 parental luciferase vector. Transfections were normal-
ized to the activity of a cotransfected pCMV-L-gal plasmid. The re-
sults are shown as meansXS.D.
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was measured. The basal transcriptional activity progressively
increased with the length of the 5P upstream region of the
human TRAIL-R3 promoter (Fig. 2). These results indicate
that all these regions appear to contain elements that contrib-
ute to the overall promoter activity and that the region span-
ning from nucleotides 333 to +42 contains the minimal pro-
moter elements of the human TRAIL-R3 gene.
3.4. Doxorubicin can induce the human TRAIL-R3 promoter
activity in a p53-independent manner
The primer extension results indicate that transcriptional
activity of the human TRAIL-R3 gene increased when
MCF-7 cells were treated with doxorubicin. Transient trans-
fection experiments were performed to test whether the basal
transcriptional activity of these human TRAIL-R3 promoter
constructs was a¡ected upon doxorubicin treatment. To this
end, MCF-7 cells were transiently transfected and luciferase
activity was measured upon overnight treatment with doxoru-
bicin. The results indicated that the transcriptional activity of
the human TRAIL-R3 promoter-containing constructs is
stimulated by doxorubicin (Fig. 3A). As a negative control,
the 2.7 kb PCR-ampli¢ed genomic fragment was cloned in
antisense orientation into pXP2 plasmid (+42, 32700). In
these experiments the highest fold induction was displayed
by the 3506,+42 promoter fragment, thus suggesting that
the key elements responsive to doxorubicin must be located
within the 3506 and +42 bp region of the human TRAIL-R3
promoter. As a control for doxorubicin-induced promoter ac-
tivity, the construct pI-CD95 391LUC corresponding to the
CD95 gene is included. This construct contains a region of
intron I of the CD95 gene that confers regulation by p53 [26].
In order to investigate whether the induction of TRAIL-R3
promoter by doxorubicin is dependent on p53 we performed
reporter assays in MCF-7 cells expressing human papilloma
virus type 16 E6 protein, which induces p53 degradation and
thus prevents p53 accumulation in response to genotoxic dam-
age [24]. Results shown in Fig. 3B indicate that p53 is not
required for doxorubicin-induced TRAIL-R3 promoter activ-
ity. In MCF-7E6 cells, the control doxorubicin-inducible, p53-
dependent pI-CD95 391LUC construct is not activated by the
DNA-damaging drug (Fig. 3B). Further evidence for the lack
of involvement of p53 in doxorubicin-induced TRAIL-R3
promoter activity in MCF-7 cells is shown in Fig. 3C. In these
co-transfection experiments, the control p53-inducible pI-
CD95 391LUC plasmid is clearly activated by wt p53 (nine-
fold). In contrast, co-transfection of the TRAIL-R3 promoter
construct (3506, +42) and wt p53 vector does not result in
transcriptional activation over the baseline activity of empty
vector-transfected cells.
To determine whether or not endogenous expression of
TRAIL-R3 could be increased by doxorubicin in a p53-de-
pendent manner, RT-PCR experiments were carried out. As
shown in Fig. 3D, doxorubicin e⁄ciently induces the endog-
enous TRAIL-R3 mRNA level in MCF-7 cells. Likewise,
doxorubicin was able to increase the TRAIL-R3 mRNA levels
in the absence of wt p53 (MCF-7E6). In these experiments, the
doxorubicin-mediated induction of TRAIL-R3 mRNA was
stronger in MCF-7 cells, therefore suggesting that p53 medi-
ates additional signals that contribute to TRAIL-R3 gene ex-
pression.
4. Discussion
In spite of the advance in the human genome sequence and
the mapping of the TRAIL receptors to the same chromosom-
al locus, 8p22^21 [8,30,31], the sequence of the human
TRAIL-R3 gene is still unknown. In this work we have cloned
and de¢ned the minimal promoter region of this decoy recep-
tor. Our results indicate that the smallest promoter construct
analyzed containing the TATA box is enough to drive the
expression of the TRAIL-R3 human gene promoter. The tran-
scriptional activity progressively increases with the size of the
5P fragment of the promoter. This suggests that functional
binding sites for transcription factors that cooperate with
the basal transcription machinery to control human TRAIL-
R3 mRNA expression must be located upstream of this min-
imal promoter fragment.
In this study, several transcription start sites were found in
non-treated MCF-7 breast carcinoma cells. It is particularly
relevant that upon doxorubicin treatment, there is an increase
in the rate of transcription from two major start sites. As a
result, the amount of mRNA and protein expressed would
probably increase and the ¢nal impact could result in the re-
sistance of these cells to TRAIL-induced apoptosis. Doxoru-
bicin is a drug currently used for breast cancer treatment and
the results from our work suggest that treatment of breast
carcinoma cells could raise the level of this decoy receptor
in these cells. This should be considered in potential clinical
trials employing TRAIL as an anti-cancer agent.
The transcriptional regulation of the TRAIL receptors has
been approached in a few studies. Rel/NF-UB transcription
factors have been shown to protect TRAIL-induced apoptosis
by up-regulating the human TRAIL-R3 expression in HeLa
cervical carcinoma cells [22]. As a new level of transcriptional
regulation, it has been suggested that hypermethylation of the
promoter of the TRAIL decoy receptors, human TRAIL-R3
Fig. 3. Doxorubicin (doxo) can induce TRAIL-R3 promoter in a
p53-independent manner. MCF-7 (A) and MCF-7E6 cells (B) were
transfected with the reporter plasmids indicated in the ¢gure, con-
taining either the human TRAIL-R3 promoter or the CD95 intronic
p53-responsive enhancer element. Ten hours after transfection, cells
were overnight treated with doxorubicin at 500 ng/ml. C: MCF-7
cells were co-transfected with the constructs indicated in the ¢gure
and a p53 expression vector. Luciferase activity is expressed as fold
induction over the baseline levels of transfected untreated cells (A,
B) or wt p53/empty vector-transfected cells (C). One out of three ex-
periments performed is shown. D: RT-PCR products from cells ei-
ther treated (+) or not (3) with doxorubicin (500 ng/ml for 24 h)
were analyzed in the p53-positive (MCF-7) or p53-negative (MCF-
7E6) cell lines.
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and TRAIL-R4, is involved in the down-regulation of the
expression of these genes in neuroblastoma and other tumor
types, such as brain, colon and skin cancers [18]. Moreover, it
has been shown that TRAIL-R3 is a p53-regulated gene
highly expressed in primary tumors of gastrointestinal tract
[21]. Although we have not observed p53-mediated regulation
of the TRAIL-R3 promoter, we cannot exclude that p53-re-
sponsive sites may be located in other regions of the gene, as
occurs in TRAIL-R2 and CD95 genes [32,33]. These sites
could account for the higher induction of TRAIL-R3 gene
expression observed in p53-positive MCF-7 cells versus
MCF-7E6 cells. In addition, treatment with doxorubicin may
also activate other transcription factors, like NF-UB and AP-1
[34,35]. In this context, this work could be the starting point
for the analysis of the human TRAIL-R3 gene at the tran-
scriptional level. Based on computer analysis, di¡erent tran-
scription factors could bind to the human TRAIL-R3 pro-
moter region and regulate its expression. Further studies
dissecting the cis- and trans-acting elements involved in the
transcriptional regulation of TRAIL-R3 promoter will facili-
tate the study of the mechanisms that control the expression
of this anti-apoptotic decoy receptor, a protein with tumor
resistance properties.
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